| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Jim van Os | Q2214357 |
| Bart P. Rutten | Q48374542 | ||
| Harry W M Steinbusch | Q55178235 | ||
| Frans RJ Verhey | Q68596187 | ||
| Gunter Kenis | Q114446513 | ||
| P2093 | author name string | Pieter Jelle Visser | |
| Bart P F Rutten | |||
| Odette Peerbooms | |||
| Leonidas Chouliaras | |||
| Daniel L A van den Hove | |||
| P2860 | cites work | Crystal structure of the nucleosome core particle at 2.8 A resolution | Q22122355 |
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 498-510 | |
| P577 | publication date | 2010-01-25 | |
| P1433 | published in | Progress in Neurobiology | Q15716615 |
| P1476 | title | Epigenetic regulation in the pathophysiology of Alzheimer's disease | |
| P478 | volume | 90 |
| Q48225902 | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression. |
| Q35969222 | A life course approach to the development of mental skills |
| Q61811401 | Age-related Disturbances in DNA (hydroxy)methylation in APP/PS1 Mice |
| Q47578572 | Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease. |
| Q36580097 | Age-related increase in levels of 5-hydroxymethylcytosine in mouse hippocampus is prevented by caloric restriction |
| Q48222289 | Aging alters mRNA expression of amyloid transporter genes at the blood-brain barrier |
| Q22252311 | Alzheimer mechanisms and therapeutic strategies |
| Q26778149 | Alzheimer's Disease: Mechanism and Approach to Cell Therapy |
| Q28394199 | Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics |
| Q37825690 | Alzheimer's disease: aging, insomnia and epigenetics |
| Q30385357 | Amyloid Beta-Mediated Hypomethylation of Heme Oxygenase 1 Correlates with Cognitive Impairment in Alzheimer's Disease |
| Q53415989 | Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. |
| Q37980082 | An interdisciplinary fetal/neonatal neurology program |
| Q34263148 | Birth size and brain function 75 years later |
| Q38224066 | Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases |
| Q48104839 | Changes in methylation patterns of multiple genes from peripheral blood leucocytes of Alzheimer's disease patients |
| Q41452742 | Chronic cerebrovascular hypoperfusion affects global DNA methylation and histone acetylation in rat brain |
| Q89514275 | Comprehensive analysis of PM20D1 QTL in Alzheimer's disease |
| Q37638856 | Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. |
| Q42874994 | Current concepts in Alzheimer's Disease: molecules, models and translational perspectives |
| Q36339504 | DNA Methylation and Tag SNPs of the BDNF Gene in Conversion of Amnestic Mild Cognitive Impairment into Alzheimer's Disease: A Cross-Sectional Cohort Study |
| Q37091491 | DNA methylation in repetitive elements and Alzheimer disease |
| Q35159029 | DNA methylation in white blood cells: association with risk factors in epidemiologic studies |
| Q50581281 | DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. |
| Q52149259 | DNMT3A rs1550117 Polymorphism is Associated With Late-Onset Alzheimer's Disease in a Chinese Population. |
| Q37969732 | Developmental origins of cerebrovascular disease II: considering gene-environment interactions when developing neuroprotective strategies |
| Q38583222 | Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. |
| Q36290480 | Dynamics of DNA methylation in aging and Alzheimer's disease |
| Q30574640 | EZH2-mediated H3K27 trimethylation mediates neurodegeneration in ataxia-telangiectasia |
| Q34259659 | Effect of synthetic aβ peptide oligomers and fluorinated solvents on Kv1.3 channel properties and membrane conductance |
| Q38842756 | Effects of chronic variable stress on cognition and Bace1 expression among wild-type mice |
| Q58777465 | Environmental Enrichment Improves Cognitive Deficits, AD Hallmarks and Epigenetic Alterations Presented in 5xFAD Mouse Model |
| Q38199061 | Environmental factors in the development and progression of late-onset Alzheimer's disease |
| Q34496410 | Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2 |
| Q61818127 | Epigenetic Factors in Late-Onset Alzheimer's Disease: and Gene Polymorphisms, Metabolic Transsulfuration and Methylation Pathways, and B Vitamins |
| Q48427246 | Epigenetic Features Induced by Ischemia-Hypoxia in Cultured Rat Astrocytes |
| Q38225708 | Epigenetic drug discovery for Alzheimer's disease |
| Q97570185 | Epigenetic mechanisms in Alzheimer's disease |
| Q38379396 | Epigenetic mechanisms in neurological and neurodegenerative diseases |
| Q28297936 | Epigenetic mechanisms of neurodegeneration in Huntington's disease |
| Q33841944 | Epigenetic regulation of adult neural stem cells: implications for Alzheimer's disease |
| Q38733322 | Epigenetic regulation of mitochondrial function in neurodegenerative disease: New insights from advances in genomic technologies |
| Q31028501 | Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease |
| Q37626479 | Epigenetic studies in Alzheimer's disease: current findings, caveats, and considerations for future studies |
| Q37962584 | Epigenetic treatment of neurological disease |
| Q92905568 | Epigenetics and Neurological Disorders in ART |
| Q26772028 | Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response |
| Q50437564 | Epigenetics of Huntington's Disease |
| Q85263415 | Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics |
| Q38664541 | Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease. |
| Q38752028 | Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents |
| Q39567162 | Gene-environment interaction in Alzheimer's disease |
| Q34189447 | Gene-environment interaction research and transgenic mouse models of Alzheimer's disease |
| Q53375184 | Genetics and epigenetics of Parkinson's disease. |
| Q36838757 | Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. |
| Q36024840 | Genome-wide alteration of 5-hydroxymenthylcytosine in a mouse model of Alzheimer's disease |
| Q39292877 | Genome-wide analysis of DNA methylation in an APP/PS1 mouse model of Alzheimer's disease. |
| Q39884125 | Ginsenoside Reduces Cognitive Impairment During Chronic Cerebral Hypoperfusion Through Brain-Derived Neurotrophic Factor Regulated by Epigenetic Modulation |
| Q38197952 | Glial epigenetics in neuroinflammation and neurodegeneration |
| Q37665547 | Histone deacetylase 2 in the mouse hippocampus: attenuation of age-related increase by caloric restriction |
| Q38060650 | Histone methylation in the nervous system: functions and dysfunctions |
| Q89608081 | Identifying lncRNA-miRNA-mRNA networks to investigate Alzheimer's disease pathogenesis and therapy strategy |
| Q97519815 | Improvements to Healthspan Through Environmental Enrichment and Lifestyle Interventions: Where Are We Now? |
| Q41326008 | MTHFR Gene Mutations: A Potential Marker of Late-Onset Alzheimer's Disease? |
| Q37085758 | Micro- and nanofluidic technologies for epigenetic profiling |
| Q35629123 | MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease |
| Q42226744 | Milk's Role as an Epigenetic Regulator in Health and Disease |
| Q36393233 | Milk: an epigenetic amplifier of FTO-mediated transcription? Implications for Western diseases |
| Q93166880 | Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease |
| Q26822451 | Nucleolar dysfunction in Huntington's disease |
| Q38046539 | Overlapped metabolic and therapeutic links between Alzheimer and diabetes. |
| Q62780620 | PM20D1 is a quantitative trait locus associated with Alzheimer’s disease |
| Q33616120 | Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly |
| Q58555658 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases |
| Q92668853 | Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer's disease model |
| Q35968810 | Prevention of age-related changes in hippocampal levels of 5-methylcytidine by caloric restriction. |
| Q34648668 | Quality evaluation of methyl binding domain based kits for enrichment DNA-methylation sequencing |
| Q35137888 | Radio electric asymmetric brain stimulation in the treatment of behavioral and psychiatric symptoms in Alzheimer disease |
| Q38020256 | Recent advances in nutrition, genes and brain health |
| Q47162103 | Regulation of neuronal survival by DNA methyltransferases |
| Q37101691 | Resilience in mental health: linking psychological and neurobiological perspectives |
| Q37627142 | Rpph1 Upregulates CDC42 Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with miR-330-5p |
| Q37856261 | Sensorimotor integration and psychopathology: motor control abnormalities related to psychiatric disorders |
| Q28564318 | Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. |
| Q53319436 | Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits. |
| Q90613241 | System biology approach intersecting diet and cell metabolism with pathogenesis of brain disorders |
| Q26771812 | Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases |
| Q38036916 | Targeting synaptic dysfunction in Alzheimer's disease therapy. |
| Q40506926 | The APOE Gene is Differentially Methylated in Alzheimer's Disease. |
| Q35864850 | The adverse effects of air pollution on the nervous system |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q38212988 | The genetic basis for aortic aneurysmal disease. |
| Q38365416 | The human β-amyloid precursor protein: biomolecular and epigenetic aspects |
| Q35055739 | The redox basis of epigenetic modifications: from mechanisms to functional consequences. |
| Q37978548 | The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy |
| Q38459830 | The role of epigenomics in the neurodegeneration of ataxia-telangiectasia |
| Q37848839 | Therapeutic prospects for epigenetic modulation |
| Q42149605 | Transcriptional signatures mediated by acetylation overlap with early-stage Alzheimer's disease |
| Q30543926 | Transcriptomics of cortical gray matter thickness decline during normal aging |
| Q34137377 | Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases |
| Q35186435 | Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. |
| Q35832672 | Using DNA methylation to understand biological consequences of genetic variability. |
Search more.